• Hyundai Bioscience will hold an extraordinary shareholders meeting on Dec. 9, 2026, at 10 a.m. at its Gimcheon headquarters.
• Shareholders will vote on Kim Jin-seok’s reappointment as independent director and Cho Yong-ho’s appointment as full-time auditor, each for three years.
• The proposed directors’ compensation cap for the 27th fiscal year is 500 million won, down from the previously proposed 2 billion won.
• The proposed auditor compensation cap is 80 million won, reduced from 200 million won.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyundai Bioscience Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261023900716), on October 23, 2026, and is solely responsible for the information contained therein.